Cargando…
Vaccine coverage and effectiveness against laboratory-confirmed symptomatic and severe Covid-19 in indigenous people in Brazil: a cohort study
BACKGROUND: Indigenous people have historically suffered devastating impacts from epidemics and continue to have lower access to healthcare and be especially vulnerable to respiratory infections. We estimated the coverage and effectiveness of Covid-19 vaccines against laboratory-confirmed Covid-19 c...
Autores principales: | Pescarini, Julia M., Cardoso, Andrey M., Santos, Ricardo Ventura, Scaff, Priscila F., Paixao, Enny S., Ranzani, Otavio T., Cerqueira-Silva, Thiago, Boaventura, Viviane S., Bertoldo-Junior, Juracy, de Oliveira, Vinicius A., Werneck, Guilherme L., Barreto, Mauricio L., Barral-Netto, Manoel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311776/ https://www.ncbi.nlm.nih.gov/pubmed/37386490 http://dx.doi.org/10.1186/s12889-023-16196-4 |
Ejemplares similares
-
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2022) -
Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case–control study
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2023) -
CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study
por: Paixao, Enny S., et al.
Publicado: (2022) -
Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2022) -
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2022)